Skip to content

Author

M. Faiyazuddin

We have 4 of 86 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Bioaugmented ZnO/MoO₃-activated carbon nanocomposite as platform for antibacterial, wound healing efficacy with embryonic toxicity assessment.

Bacterial infections obstruct wound healing, prolong inflammation and disrupt cellular activity, leading to chronic wound formation. Consequently, the development of advanced therapeutic strategies like nanomedicine and biocompatible materials has become increasingly important. To address these biological barriers, bio...

Kaviya Suresh, M. Faiyazuddin, P. Dharmaraj et al. · 0 citations
Review Open access Sep 2026

Recent advances in hormone-based biopharmaceuticals for cancer therapy

Hormone-dependent cancers, particularly estrogen receptor-positive breast cancer and androgen receptor-driven prostate cancer, contribute substantially to global cancer-related morbidity and mortality. Endocrine therapy has long been the mainstay of treatment for these tumors because of its specific mechanism and good...

Syahmi Nuqman Sarifulnazwan, Nur Alia Fatihah Mohd Tajuddin, Siti Nur Nadhirah Mohd Nasaruddin et al. · 0 citations
Review Open access Aug 2026

IL-15 Superagonists for Reprogramming the Immunosuppressive Microenvironment in Gastrointestinal Adenocarcinomas.

Gastrointestinal (GI) adenocarcinomas pose a significant therapeutic challenge due to highly immunosuppressive tumor microenvironments that limit effective antitumor immune responses. Dense stromal fibrosis, immune exclusion and poor responses to immune checkpoint inhibitors are hallmarks of treatment-resistant maligna...

Neeraj Choudhary, M. Faiyazuddin, R. Kamal et al. · 0 citations
Aug 2026

Bioengineered ZnO/Activated Carbon Nanocomposites for Combating Multidrug-resistant Bacterial Strains

The present work highlights the superior physicochemical and antibacterial performance of BZNAC compared with BZN, underscoring the synergistic effect of AC inclusion and validating BZNAC as a therapeutic candidate against MDR bacterial infections, warranting further preclinical and clinical testing.

Kaviya Suresh, S. Antony, M. Faiyazuddin et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.